Wednesday, December 30, 2020 4:09:24 PM
I should think that 'sellers' are queueing round the block while 'buyers' are somewhat thinner on the ground.
And even then, those 'buyers' are merely taking bets on the value of realisable/liquidisable assets upon or immediately prior to liquidation. e.g. how much would the diabetes strip wholesalers pay for the Genultimate 510K to keep their supply chain open? How much would the South Korean partner value the 510K at that would allow then to market the strips themselves direct?
Current valuation does not set that at a very big number. But it is still a probably vast over estimate imo.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM